In non-diabetic NAFLD patients, a 4-weeks of treatment with the non-steroidal FXR agonist PX-104 improved liver enzymes and insulin sensitivity with no serious adverse events. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.